Propantheline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Propantheline: From Peptic Ulcer Disease to Gastroduodenitis
One-Sentence Summary
Propantheline is a classic antimuscarinic (anticholinergic) agent historically used to reduce gastric acid secretion and gastrointestinal spasm, with reported use as an adjunct in peptic ulcer disease. The TxGNN model predicts it may also be effective for Gastroduodenitis, but this direction is currently supported only by older comparative and cohort literature — 0 registered clinical trials and 5 relevant publications, one of which is a completed double-blind trial that found no added benefit over standard therapy alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the ARTG (Propantheline is not currently marketed in Australia). Historical literature describes it as an antimuscarinic adjunct for peptic ulcer disease and GI spasm |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L3 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for propantheline is not currently available in this evidence pack (DrugBank query returned a data gap). Based on known pharmacology, propantheline is a synthetic antimuscarinic (anticholinergic) agent that reduces gastric acid secretion and gastrointestinal motility — the same class of action documented in historical trials as an adjunct treatment for peptic ulcer disease.
Gastroduodenitis and peptic ulcer disease share substantial pathophysiological overlap: both involve acid-related mucosal injury to the stomach and duodenum, and both have historically been managed with antisecretory/antispasmodic agents. This mechanistic proximity is why the TxGNN model’s prediction is biologically plausible rather than arbitrary.
However, the strongest single piece of clinical evidence available (PMID 6342335, a double-blind comparative trial) found no significant difference in ulcer healing or symptom relief when propantheline was added to cimetidine versus cimetidine alone. This tempers the mechanistic rationale considerably — the historical evidence base suggests biological relevance but not necessarily added clinical benefit over modern antisecretory therapy.
Clinical Trial Evidence
Currently no related clinical trials registered for gastroduodenitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6342335 | 1983 | Comparative trial (double-blind) | Acta medica Scandinavica | 58 patients with endoscopically verified gastric/duodenal ulcers; cimetidine + propantheline vs cimetidine + placebo showed no significant difference in ulcer healing or symptom relief at 3 or 6 weeks |
| 817194 | 1976 | Cohort | MMW, Münchener medizinische Wochenschrift | Combination preparation (including propantheline-class agent) for inflammatory/ulcerous gastroduodenal disease; marked symptomatic improvement, but stenosis/ileus noted as contraindications |
| 4798570 | 1973 | Review | Minerva medica | Conservative therapy overview for gastroduodenal ulcer (no abstract available) |
| 13392433 | 1956 | Case series | Vie médicale (Paris) | Early (pre-RCT era) report on anticholinergic treatment of gastroduodenal ulcer using propantheline |
| 761954 | 1979 | Other (pharmacokinetic comparator, not propantheline-focused) | Int J Clin Pharmacol Biopharm | Trithiozine bioavailability study using propantheline bromide as a pharmacological comparator for gastric secretion suppression |
Australia Market Information
Propantheline currently has no ARTG entries and is not marketed in Australia.
Safety Considerations
No TGA-approved Product Information currently exists for Propantheline in Australia, as the drug is not marketed here. No key warnings, contraindications, or drug interaction data were retrieved in this evidence pack (DDI query: not found). Safety information should be sourced from an established overseas Product Information, AMH, or Martindale reference before any clinical use is considered.
Conclusion and Next Steps
Decision: Research Question
Rationale: Mechanistic plausibility for gastroduodenitis is reasonable given propantheline’s antisecretory/antispasmodic action and historical use in peptic ulcer disease, but the only comparative trial identified found no significant added benefit, and no dedicated clinical trials for gastroduodenitis are currently registered. Combined with the drug’s absence from the Australian market, evidence remains preliminary and hypothesis-generating rather than decision-ready.
To proceed, the following is needed:
- Detailed mechanism of action data (currently a data gap)
- A Product Information / equivalent safety and contraindication dataset — this is currently a blocking gap for any safety pre-assessment, since the drug has no ARTG-registered PI
- Dedicated, adequately powered clinical trials evaluating propantheline specifically for gastroduodenitis (current evidence is indirect and largely pre-1990)
- Drug–drug interaction data, currently unavailable
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.